Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 9

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR

Authors Kuecker C, Vivian E

Received 23 September 2015

Accepted for publication 21 January 2016

Published 23 February 2016 Volume 2016:9 Pages 25—35

DOI https://doi.org/10.2147/DMSO.S81565

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Prof. Dr. Ahmed R. G.

Peer reviewer comments 2

Editor who approved publication: Professor Ming-Hui Zou


Catherine M Kuecker, Eva M Vivian

Pharmacy Practice Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA

Purpose: The purpose of this review article is to provide guidance to health care providers regarding the use of dapagliflozin–metformin XR (extended release) as a therapeutic option for the treatment of patients with type 2 diabetes mellitus (T2DM).
Methods: The PubMed database was searched through August 2015 to identify clinical trials and meta-analyses evaluating the use of the sodium–glucose cotransporter type 2 inhibitor dapagliflozin administered as monotherapy or in combination with metformin.
Results: Fourteen studies were included for this review, six of which evaluated dapagliflozin in combination with metformin, one of which evaluated dapagliflozin monotherapy, and four of which evaluated dapagliflozin as an add-on therapy to other antidiabetic agents. The combination of dapagliflozin and metformin resulted in an A1C decrease of up to 2%, weight loss of 2–3 kg, and modest systolic blood pressure decrease of 3–5 mmHg. However, long-term effects on cancer and cardiovascular health are still being investigated. Providing patients with a fixed-dose combination therapy such as dapagliflozin-metformin XR can increase medication adherence and patient satisfaction, and improve glycemic control. Dapagliflozin–metformin XR is ideal because it can be administered orally once a day, is associated with a low risk of hypoglycemia, and provides the added benefit of weight reduction and modest blood pressure lowering.
Conclusion: The unique combined mechanism of action and favorable efficacy and safety profile of dapagliflozin–metformin XR support consideration of this fixed-dose combination as a treatment option for patients with T2DM.

Keywords: fixed-dose combination therapy, metformin, SGLT2 inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]